SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,111,281. The last known price of Bitcoin is 71,086.72423286 USD and is down -3.89 over the last 24 hours. It is currently trading on 12779 active market(s) with $28,515,435,687.36 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoins steep selloff is driving attention, with traders pointing to leveraged long liquidations and broader risk-off pressure. The community is split between buying an oversold dip near technical support and expecting further declines if selling continues.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Phase 3 REGAL trial of GPS has reached the 80th event, and the company expects topline results this month, driving intense attention ahead of the AML data readout. Traders celebrated a sharp after-hours move and speculated about a data leak or short covering, while others cautioned that the trial remains blinded and its outcome is unknown.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MSCIs decision to remove Strategy from its indexes is fueling concerns about passive fund selling, while Bitcoins decline adds pressure to the stock. Traders debate whether the potential outflows are already priced in and whether the exclusion will materially weaken Strategys Bitcoin-linked financing model.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

A widespread Microsoft 365 outage disrupted Outlook, Teams, Copilot and other services, prompting complaints from users whose work was interrupted. Traders debated whether the prolonged disruption should pressure the stock, which held near flat-to-positive, while some speculated about a cyberattack without confirmation.

XRP (XRP) is a cryptocurrency . XRP has a current supply of 99,985,583,260 with 63,516,606,953 in circulation. The last known price of XRP is 1.03439229 USD and is down -2.16 over the last 24 hours. It is currently trading on 1895 active market(s) with $1,786,076,895.36 traded over the last 24 hours. More information can be found at https://xrpl.org/.

Ripple

XRP is sliding alongside a broader crypto selloff, with traders pointing to risk-off sentiment, inflation and rate-hike concerns, and leveraged liquidations. The steep decline has sparked debate over whether support will hold or losses will deepen, while some holders are buying the dip and others cite stalled regulatory progress and weak demand as reasons for caution.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Jensen Huangs resignation and Colette Kresss interim appointment have rattled NVDA shares, with traders also debating potential China chip-export scrutiny and the companys reliance on Huangs leadership. The community is split between buying the selloff on confidence in Nvidias AI business and avoiding the stock amid leadership and regulatory uncertainty.

Zcash (ZEC) is a cryptocurrency . Users are able to generate ZEC through the process of mining. Zcash has a current supply of 16,962,604.07029401. The last known price of Zcash is 956.58767703 USD and is down -2.92 over the last 24 hours. It is currently trading on 670 active market(s) with $828,877,374.43 traded over the last 24 hours. More information can be found at https://z.cash/.

Zcash

Zcashs sharp pullback after a major rally is dominating discussion, with traders debating whether it is a broader crypto-market correction and liquidation flush or a deeper breakdown. Some call the selloff an oversold buying opportunity, while bears point to lost support and continued selling.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candels planned prostate-cancer BLA filing has been pushed to mid-2027 amid FDA discussions and assay refinement, prompting a sharp selloff and criticism of managements communication and credibility. Some traders see the delay as a manufacturing and regulatory hurdle rather than a problem with the clinical data, while others remain concerned about execution and the longer wait.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase is under pressure alongside Bitcoins slide and broader weakness in crypto-linked stocks, with traders highlighting fresh lows and arguing over whether the selloff has further to run or the shares are forming a base. Some also point to COINs underperformance versus Bitcoin and concerns about trading activity, while a smaller group sees an oversold bounce opportunity.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

BMNR is drawing attention amid weakness in Ethereum and broader crypto-linked stocks, with traders focused on its ETH-treasury exposure and the shares decline. The community is split between dip-buyers expecting a recovery and critics questioning Tom Lees strategy, company spending, transparency and buybacks.

statis crypto Watchlist

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Gland Pharma Secures USFDA Tentative Approval for Generic Lumify Eye Drops

Hyderabad: Gland Pharma Limited has announced that it … the United States. Gland Pharma , headquartered in Hyderabad, is a pharmaceutical company primarily focused … powders, infusions, oncology drugs , and ophthalmic solutions. Gland Pharma is also known …

Gland Pharma Names Dr Jitendra Gangwal Vice President, Research & Development

New Delhi: Gland Pharma has appointed Dr … institutions and leading Indian pharmaceutical companies. Over the course … . Prior to joining Gland Pharma , Dr. Gangwal was associated … . Reddy’s Laboratories, Glenmark Pharmaceuticals , Alkem Laboratories, and FDC …

Brief India: Aequitas: Aditya Infotech IPO Lockup Expiry- Has Continued Its Good Run, Dixon Tech Could Book Gains and more

In this briefing: Aequitas: Aditya Infotech IPO Lockup Expiry- Has Continued Its Good Run, Dixon Tech Could Book Gains LG Electronics India (Initiating Coverage): Steering Through Winds of Leadership and Innovation. ADD SBI Life Insurance Co Ltd - Strong Quarter; Business Momentum to Continue! Maruti Suzuki Ltd - Export Momentum Supports Growth; Domestic Competition Remains Intense Gland Pharma Ltd - Visible Turnaround in Cenexi with Strong Base 1. Aequitas: Aditya Infotech IPO Lockup Expiry- Has Continued Its Good Run, Dixon Tech Could Book Gains Aditya Infotech Ltd (6596564Z IN) (AIL) raised around US$151m in its IPO in August 2025. The lockup on its pre-IPO investors is set to expire soon. AIL is a CCTV/video surveillance provider company offering a range of advanced video security and surveillance products, technologies and solutions for enterprise and consumer segments under its CP PLUS brand. In this note, we will talk about the lockup dynamics and possible placement. 2. LG Electronics India (Initiating Coverage): Steering Through Winds of Leadership and Innovation.

Brief India: LG Electronics India (Initiating Coverage): Steering Through Winds of Leadership and Innovation. ADD and more

In this briefing: LG Electronics India (Initiating Coverage): Steering Through Winds of Leadership and Innovation. ADD SBI Life Insurance Co Ltd - Strong Quarter; Business Momentum to Continue! Maruti Suzuki Ltd - Export Momentum Supports Growth; Domestic Competition Remains Intense Gland Pharma Ltd - Visible Turnaround in Cenexi with Strong Base TVS Motor Co Ltd - Twin Growth Drivers: EV Expansion & Export Strength 1. LG Electronics India (Initiating Coverage): Steering Through Winds of Leadership and Innovation. ADD We initiate coverage on LG Electronics India (LG) with an ADD rating and a TP of INR 1,545 per share, valuing it at 38x Mar-28E AEPS We like LG for its market leadership in core product categories, strong brand equity, consistent technological innovations and product launches, healthy balance sheet, robust return ratios, and low working capital needs LG is a leading player in washing machines, refrigerators, panel televisions, and inverter ACs. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

Brief India: Maruti Suzuki Ltd - Export Momentum Supports Growth; Domestic Competition Remains Intense and more

In this briefing: Maruti Suzuki Ltd - Export Momentum Supports Growth; Domestic Competition Remains Intense Gland Pharma Ltd - Visible Turnaround in Cenexi with Strong Base TVS Motor Co Ltd - Twin Growth Drivers: EV Expansion & Export Strength Primer: Jammu & Kashmir Bank (JKBK IN) - Jan 2026 Exencial Industry Tidings 1. Maruti Suzuki Ltd - Export Momentum Supports Growth; Domestic Competition Remains Intense Domestic Market Share & Profitability Outlook: Domestic demand witnessed a sharp inflection in Q3FY26 following the government’s landmark GST reduction, which catalysed industry growth to ~20.5% YoY versus a decline of ~0.4% in H1FY26. MSIL outperformed the industry with domestic volume growth of ~22%, supported by strong traction across small cars and SUVs. Management highlighted a revival in the small car segment, which transitioned from a “red zone” of negative growth to healthy expansion, aided by improved affordability and a 7% rise in first-time buyers, particularly upgrades from two-wheelers.

Gland Pharma Shares Surge Over 9%, Q3 FY26 Profit Rises 28% To ₹261 Crore

Gland Pharma shares surged over 9 percent after Q3 FY26 profit rose 28 percent and revenue grew 23 percent. Strong product launches, higher R&D spending, and heavy trading volumes boosted investor sentiment.The strong stock movement came after the Hyderabad-based drug maker announced its financial results for the third quarter of FY26 after market hours on Wednesday.

Gland Pharma Gets USFDA Approval for Olopatadine Ophthalmic Solution

… Regulations, 2015, Gland Pharma stated that the USFDA approval … United States market. Gland Pharma , established in 1978 and … injectable and ophthalmic-focused pharmaceutical company with operations across … in India. Gland Pharma stated that the approval …

These two companies will sell shovels during India’s semaglutide gold rush

Shaily Engineering Plastics Ltd and Gland Pharma Ltd, involved in the making and filling of injectable pens for semaglutide, stand to win big as patients will need these devices irrespective of which brand of the drug they choose.

Brief India: PVR’s Two-Front War: Defending Premium SPH While Chasing Asset-Light Scale and more

In this briefing: PVR’s Two-Front War: Defending Premium SPH While Chasing Asset-Light Scale Gland Pharma Ltd - Poised for Stronger H2 Momentum; Rating Upgraded to BUY Westlife Foodworld Ltd - Resilience Amid Demand Softness; Maintain BUY Auto Monthly Sales Volume - October 2025 NOCIL Ltd - Pricing Pressure Continues; Global Uncertainties Adding to the Woes 1. PVR’s Two-Front War: Defending Premium SPH While Chasing Asset-Light Scale PVR Inox is piloting a full-service "dine-in" cinema concept in Bengaluru, while management confirms a major strategic shift towards an asset-light (FOCO) model for new screen expansion. The dine-in is a defensive move to protect premium Spend Per Head (SPH) against OTT, while the asset-light pivot is move to fix the balance sheet and scale in Tier-2/3. The company is re-engineering its business to be less dependent on its own capital, but its profitability remains entirely dependent on the one thing it cannot control: the content pipeline . 2. Gland Pharma Ltd - Poised for Stronger H2 Momentum; Rating Upgraded to BUY Stable Core and Cenexi Turnaround Drive Revenue Growth: Gland Pharma reported consolidated revenue of Rs 1,487 Cr in Q2FY26, marking a 5.8% YoY growth, in line with our estimates.

Pharma stocks crack, Nifty Pharma Index slips over 2% as Trump unveils 100% tariff: 3 key factors investors must watch

… and patented drugs entering … pharma space include the likes of Natco Pharma , Laurus Labs, Alembic Pharma , Sun Pharma … , Gland Pharma , Ajanta Pharma , and Glenmark Pharmaceuticals … of Indian pharmaceutical exports. …

Gland Pharma Ltd. manufactures pharmaceutical ingredients and injectable formulations. It offers injectables including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, and ophthalmic solutions. The company was founded by P. V. N. Raju in 1978 and is headquartered in Sangareddy, India.

Gland Pharma Ltd.

India’s Healthcare Index Sinks After Trump’s Pharma Tariff Blow — SEBI Analyst Sees Risks For Gland, Biocon, Dr. Reddy’s

Equity

Neutral Sentiment

Healthcare stocks in India fell on Friday as investors weighed the impact of U.S. President Donald Trump’s move to impose a 100% tariff on branded and patented drugs starting Oct. 1.&nbsp;The measure, announced in late-night Truth Social posts, exempts only those manufacturers with U.S. plants that are already under construction or have broken ground.The Nifty Healthcare index fell 1.2% on Thursday, with 18 of its 20 components trading lower.&nbsp;IPCA Laboratories remained unchanged, while Torrent Pharma rose 0.01%.Analyst ViewSEBI-registered analyst&nbsp;<a href="https://stocktwits.com/ra_vishaltrehan">Vishal Trehan</a> said Gland Pharma is the most exposed, given its lack of a U.S. manufacturing footprint and reliance on branded or patented formulations.&nbsp;<stembedurl>https://stocktwits.com/ra_vishaltrehan/message/630078378</stembedurl>He noted that Syngene International, Piramal Pharma, and Zydus Lifesciences stand to benefit from their contract manufacturing models and biologics portfolios, which are less tariff-sensitive.Trehan also pointed out that companies with a large branded generics or biosimilars presence, such as Dr. Reddy’s Laboratories and Biocon, will need to accelerate U.S. production to avoid margin erosion.Trump’s Pharma TariffsThe announcement builds on Trump’s escalating trade measures aimed at repatriating drug manufacturing. Last month, he outlined a phased plan, beginning with a “small tariff” on imported drugs, before lifting duties to 150% within 18 months and ultimately to 250%.&nbsp;Pharmaceuticals had earlier been excluded from his reciprocal tariff program, but the new rules extend to prescription medicines, biologics, specialty drugs, and over-the-counter products, with generic drugs remaining exempt.What Is The Retail Mood?On Stocktwits, retail sentiment for Piramal Pharma, Zydus Lifesciences, and Dr. Reddy’s Laboratories was ‘bearish’ amid ‘normal’ message volume.So far this year,&nbsp;<a href="https://stocktwits.com/symbol/GLAND.NSE">Gland Pharma</a> has risen 6.5%, while&nbsp;<a href="https://stocktwits.com/symbol/SYNGENE.NSE">Syngene International</a> is down 29.1%,&nbsp;<a href="https://stocktwits.com/symbol/PPLPHARMA.NSE">Piramal Pharma</a> has slipped 25.9%,&nbsp;<a href="https://stocktwits.com/symbol/ZYDUSLIFE.NSE">Zydus Lifesciences</a> is up 1.8%,&nbsp;<a href="https://stocktwits.com/symbol/DRREDDY.NSE">Dr. Reddy’s Laboratories</a> is down 7.2%, and&nbsp;<a href="https://stocktwits.com/symbol/BIOCON.NSE">Biocon</a> has fallen 6.3%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

The analyst noted that Syngene, Piramal Pharma, and Zydus Lifesciences may be better positioned, as their contract manufacturing models and biologics portfolios are less susceptible to the tariff impact.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	21.00	--	--	N/A
Q2 '26	16.96	17.62	3.91%	BEAT
Q1 '26	18.56	19.22	3.54%	BEAT
Q4 '25	18.72	--	--	N/A
Q3 '25	15.78	15.87	0.58%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

GLAND.NSE Earnings

Latest Earnings Results: Q2 '26

Historical Earnings